LIVZON PHARMAC. GRP H YC1
Research LIVZON PHARMAC. GRP H YC1 (LP6) on Bullrun: market cap EUR 1.95B, P/E 9.2, dividend yield 8.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLP6
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 1.95B
- P/E9.2
- Dividend yield8.3%
- Financial periodQ1 2026
- RevenueCNY 2.87B
- Net incomeCNY 576.91M
- Free cash flowCNY 727.35M
- Gross margin65.9%
Valuation Snapshot
latest market cap is EUR 1.95B; P/E is 9.2; dividend yield is 8.3%.
Peer valuation comparison
Latest P/E is 9.17x versus a Healthcare sector median of 24.46x (62.5% below).
Latest dividend yield is 8.31% versus a Healthcare sector median of 2.11% (293.8% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 1.95B | 9.2 | 7.9% | 0.18 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.18 EUR, yield 8.3%.
About LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LIVZON PHARMAC. GRP H YC1's market cap?
LIVZON PHARMAC. GRP H YC1's market capitalization is EUR 1.95B.
What is LIVZON PHARMAC. GRP H YC1's P/E ratio?
LIVZON PHARMAC. GRP H YC1's price-to-earnings (P/E) ratio is 9.2.
Does LIVZON PHARMAC. GRP H YC1 pay a dividend?
LIVZON PHARMAC. GRP H YC1 has a dividend yield of 8.3%.
What does LIVZON PHARMAC. GRP H YC1 do?
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally.